Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-12-18
DOI
10.3389/fimmu.2018.02905
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pathogen recognition by NK cells amplifies the pro-inflammatory cytokine production of monocyte-derived DC via IFN-γ
- (2018) Tammy Oth et al. BMC IMMUNOLOGY
- Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2
- (2018) Samuele Cazzamalli et al. CLINICAL CANCER RESEARCH
- Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity
- (2018) Barbara Ziffels et al. Immunotherapy
- Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model
- (2018) Hans D. Menssen et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Chemotherapeutic drug delivery by tumoral extracellular matrix targeting
- (2018) René Raavé et al. JOURNAL OF CONTROLLED RELEASE
- Biology of IL-2 and its therapeutic modulation: Mechanisms and strategies
- (2018) Suman Mitra et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs
- (2018) Michael Dougan et al. Cancer Immunology Research
- The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses
- (2018) Nicolle H. Rekers et al. OncoImmunology
- Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
- (2017) Christian Klein et al. OncoImmunology
- Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
- (2017) Deborah Charych et al. PLoS One
- In SituTumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments
- (2016) Zachary S. Morris et al. CANCER RESEARCH
- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
- (2016) D. H. Charych et al. CLINICAL CANCER RESEARCH
- Interleukin 2 Activates Brain Microvascular Endothelial Cells Resulting in Destabilization of Adherens Junctions
- (2016) Lukasz S. Wylezinski et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2
- (2016) N. Arenas-Ramirez et al. Science Translational Medicine
- Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy
- (2016) Reza Ghasemi et al. Nature Communications
- Cyclophosphamide and tucotuzumab (huKS-IL2) following first-line chemotherapy in responding patients with extensive-disease small-cell lung cancer
- (2015) Oleg Gladkov et al. ANTI-CANCER DRUGS
- Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study
- (2015) Riccardo Danielli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Advances in the molecular functions of syndecan-1 (SDC1/CD138) in the pathogenesis of malignancies
- (2015) Rajendra Gharbaran CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy
- (2015) Michel M van den Heuvel et al. Journal of Translational Medicine
- Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature
- (2015) Niklas Börschel et al. LEUKEMIA RESEARCH
- Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma
- (2015) Sébastien Wieckowski et al. LUNG CANCER
- Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model
- (2015) Nicolle H. Rekers et al. RADIOTHERAPY AND ONCOLOGY
- Interleukin-2: Biology, Design and Application
- (2015) Natalia Arenas-Ramirez et al. TRENDS IN IMMUNOLOGY
- Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts
- (2015) Paola Orecchia et al. Oncotarget
- Targeting Interleukin-2 to the Bone Marrow Stroma for Therapy of Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
- (2015) Christoph Schliemann et al. Cancer Immunology Research
- The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy
- (2015) T. A. Waldmann Cancer Immunology Research
- Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2
- (2015) Nicolle H Rekers et al. OncoImmunology
- Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects
- (2015) C. M. L. Zegers et al. CLINICAL CANCER RESEARCH
- Armed antibodies for cancer treatment: a promising tool in a changing era
- (2014) Riccardo Danielli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy
- (2014) Francesca Pretto et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- A Think Tank of TINK/TANKs: Tumor-Infiltrating/Tumor-Associated Natural Killer Cells in Tumor Progression and Angiogenesis
- (2014) Antonino Bruno et al. JNCI-Journal of the National Cancer Institute
- Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells
- (2014) Dae Kim et al. Journal of Translational Medicine
- Antibody-Based Delivery of IL2 and Cytotoxics Eradicates Tumors in Immunocompetent Mice
- (2014) K. L. Gutbrodt et al. MOLECULAR CANCER THERAPEUTICS
- Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunologic Responses
- (2014) B. Weide et al. Cancer Immunology Research
- Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the Hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival
- (2013) Richard K. Yang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma
- (2013) Paola Orecchia et al. EUROPEAN JOURNAL OF CANCER
- The tumor microenvironment at a glance
- (2013) F. R. Balkwill et al. JOURNAL OF CELL SCIENCE
- Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent Activity Against Acute Myeloid Leukemia
- (2013) K. L. Gutbrodt et al. Science Translational Medicine
- Phase II trial of hu14.18-IL2 for patients with metastatic melanoma
- (2012) Mark R. Albertini et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Paclitaxel Enhances Therapeutic Efficacy of the F8-IL2 Immunocytokine to EDA-Fibronectin-Positive Metastatic Human Melanoma Xenografts
- (2012) M. Moschetta et al. CANCER RESEARCH
- Macrophage plasticity and polarization: in vivo veritas
- (2012) Antonio Sica et al. JOURNAL OF CLINICAL INVESTIGATION
- Intratumoral hu14.18-IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC Retention
- (2012) R. K. Yang et al. JOURNAL OF IMMUNOLOGY
- The Immunocytokine L19–IL2 Eradicates Cancer When Used in Combination with CTLA-4 Blockade or with L19-TNF
- (2012) Kathrin Schwager et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- An Il12-Il2-Antibody Fusion Protein Targeting Hodgkin's Lymphoma Cells Potentiates Activation Of Nk And T Cells For An Anti-Tumor Attack
- (2012) Tobias Jahn et al. PLoS One
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma
- (2011) T. K. Eigentler et al. CLINICAL CANCER RESEARCH
- A Low-Toxicity IL-2-Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
- (2011) S. D. Gillies et al. CLINICAL CANCER RESEARCH
- Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis
- (2010) A. Purushothaman et al. BLOOD
- Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastoma
- (2010) M Pedretti et al. BRITISH JOURNAL OF CANCER
- Genotypes of NK Cell KIR Receptors, Their Ligands, and Fc Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy
- (2010) D. C. Delgado et al. CANCER RESEARCH
- The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
- (2010) Manfred Johannsen et al. EUROPEAN JOURNAL OF CANCER
- Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study
- (2010) Suzanne Shusterman et al. JOURNAL OF CLINICAL ONCOLOGY
- The Immunocytokine F8-IL2 Improves the Therapeutic Performance of Sunitinib in a Mouse Model of Renal Cell Carcinoma
- (2010) Katharina Frey et al. JOURNAL OF UROLOGY
- Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
- (2010) C. Krieg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- KIR and HLA Genotypes Are Associated with Disease Progression and Survival following Autologous Hematopoietic Stem Cell Transplantation for High-Risk Neuroblastoma
- (2009) J. M. Venstrom et al. CLINICAL CANCER RESEARCH
- Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFα
- (2009) Enrica Balza et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
- (2009) Antoni Ribas et al. Journal of Translational Medicine
- Immune Therapy for Cancer
- (2008) Michael Dougan et al. Annual Review of Immunology
- Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2
- (2008) C. Schliemann et al. BLOOD
- Intratumoral immunocytokine treatment results in enhanced antitumor effects
- (2008) Erik E. Johnson et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Targeted Immunocytokine L19-IL2 Efficiently Inhibits the Growth of Orthotopic Pancreatic Cancer
- (2008) K. Wagner et al. CLINICAL CANCER RESEARCH
- Antibody-Mediated Delivery of Interleukin-2 to the Stroma of Breast Cancer Strongly Enhances the Potency of Chemotherapy
- (2008) J. Marlind et al. CLINICAL CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started